Guide: A Basic Overview Of Serum Protein Manual Agarose Electrophoresis
June 25th, 2019
Study: Detection Of Benzodiazepines In Oral Fluid By Homogeneous Enzyme Immunoassay
June 20th, 2019
MEDICA 2019 - World Forum for Medicine
Düsseldorf, GermanyBooth No.: 3/D35-2
AACC Annual Scientific Meeting and Clinical Lab Expo
Anaheim Convention Center ~ Anaheim, CABooth No.: 2627
Thanks to Block Scientific, I was able to procure the re-certified Bayer DCA 2000+ without hassles and get the lab back in operation. The
device works perfectly and I look forward to doing more business with Block Scientific.
--- Mathew Anderson, New Jersey
The DRG HCG ELISA is an enzyme immunoassay for the measurement of intact human chorionic gonadotropin (hCG) in serum or plasma. In the United States, this kit is intended for Research Use Only.
Chorionic Gonadotropin (hCG) is a glycoprotein hormone which is normally produced by the placenta during pregnancy. After conception, the hCG concentration increases rapidly to reach a peak near the end of the first trimester. High concentrations are observed throughout pregnancy. After delivery, hCG levels fall rapidly and become undetectable after a few days. Structurally intact hCG molecules are composed of an alpha and a beta subunit with a molecular weight of 38.4 kDa. The alpha subunit is nearly identical to the alpha subunits of other glycoprotein hormones, such as Thyroid Stimulating Hormone (TSH), Luteinizing Hormone (LH), and Follicle Stimulating Hormone (FSH): The differences in the beta subunit of the respective hormones account for their biological specificity and immunochemical distinctiveness.
Monoclonal antibodies recognizing unique sites on the beta chain of the hCG molecule are essential for differentiation between hCG and LH, FSH and TSH. HCG Assays are used for the early detection of pregnancy.
Over 50% of patients with malignant insulinomas have elevated hCG levels: the hormone
is not detected in association with benign adenomas. Ectopic secretion of hCG also have been found in a small percentage of patients with adenocarcinoma of the ovary, pancreas and stomach, hepatomas, and islet-cell carcinomas.